COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo
  • 2020s
  • 2010s
  • 2000s
  • 1990s
  • 1980s

2021

• Piramal Pharma Solutions acquires minority stake in Yapan Bio, India-Based CDMO providing expertise in Biologics and Vaccines.

Piramal 2021
19
18
Piramal 2021

2021

• Piramal Pharma Solutions completes acquisition of Hemmo Pharmaceuticals, a Leading Indian Manufacturer of Peptide APIs.

2020

• Piramal Pharma Solutions completes acquisition of Solid Oral Dosage Drug Product Facility in Sellersville, Pennsylvania from G&W Laboratories Inc

Piramal 2020
17
16
Piramal 2016

2016

• Piramal acquires Ash Stevens Inc., a US-based contract developer and manufacture of drugs specializing in high potent APIs

2015

• Piramal acquires Kentucky-based speciality pharmaceutical CDMO, Coldstream Laboratories Inc.

Piramal 2015
15
14
Piramal 2012

2012

• Piramal Healthcare Limited is renamed to Piramal Pharma Limited.

2011

  • Fortune 500 ranks Piramal Healthcare in the top-50 largest corporations across India
  • UN Conference on the Trade and Development’s World Investment Report 2011 ranks Piramal Healthcare as No.5 in the top 10 pharmaceutical contract manufactures worldwide
  • Piramal acquires Oxygen Bio-research, a CRO based in Ahmedabad, India that offers medicinal chemistry services
Piramal 2011
13
12
Piramal 2010

2010

• Piramal sells the diagnostics division to Super Religare Laboratories Ltd.

• Biosyntech, Inc., Canada is acquired by Piramal. This is a part of the Life Science vertical, bio-orthopedics division.

2005

• Avecia Pharmaceutical is acquired.

• Forbes 2005 List of ‘Best Small Asian Companies’ ranks Piramal Healthcare as a high value achiever.

Piramal 2005
11
10
Piramal 2003

2003

• Global Bulk Drugs is acquired.

• Sarabhai Piramal is acquired.

2002

• ICI Pharma is acquired.

Piramal 2002
9
8
Piramal 2000

2000

• Started collaborative research with Centre for Biochemical Technology in the field of gene technology

1998

• Acquired the research unit of Hoechst Marion Roussel (India) in Mumbai.

Piramal 1998
7
6
Piramal 1996

1996

• Boehringer Mannheim is acquired.

1995

• Acquired the bulk drug division of Sumitra Pharmaceutical and Chemicals Ltd. Hyderabad.

Piramal 1995
5
4
Piramal 1993

1993

• Piramal entered into a joint venture agreement with Allergan, the leading manufactures of ophthalmic products

1992

• Nicholas Laboratories Ltd. renamed to Nicholas Piramal India, Ltd.

Piramal 1992
3
2
Piramal 1991

1991

• Formulation plant at Pithampur in Madhya Pradesh is commissioned and later expanded in 1992

1988

• Acquired Nicholas Laboratories, initiating entry into pharmaceuticals

Piramal 1988
1